Passage Bio, Inc.

PASG Healthcare Biotechnology

In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.48 0.12 −3.33%
Market cap
$11.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Cash and Short Term Investments
46.30 76.76 114.29 189.61 315.77 304.82 158.87 24.86
Other current assets
0.83 1.22 2.74 6.51 7.57 10.96 6.75 8.54
Total current assets
47.76 78.82 117.96 197.04 325.07 317.18 165.78 33.40
Property, Plant, Equpment (Net)
4.11 9.33 15.30 22.52 23.81 2.80 1.09 0.03
Long-term assets (Other)
0.24 0.46 0.43 4.27 6.20 8.03 11.75 0.03
Total non-current assets
14.52 23.60 32.59 46.51 30.01 10.82 12.84 —
Total Assets
62.28 102.41 150.55 243.55 355.08 328.01 178.61 33.46
Accounts Payable
1.11 0.74 1.30 4.07 9.45 5.27 0.63 0.21
Accrued Expenses
4.65 6.71 11.67 11.01 20.05 15.91 3.05 —
Other current liabilities
13.75 8.23 — 11.01 20.05 15.91 3.05 0.10
Total current liabilities
23.08 19.36 16.34 18.35 29.50 21.18 3.68 0.31
Non-current Revenue (Deferred)
— — — — 6.92 2.08 0.50 —
Liabilities (Preferred Stock)
— — — — — — 230.61 —
Non-current Liabilities (Other)
— — — — — 0.04 0.08 2.21
Total non-current liabilities
20.44 21.79 22.92 23.83 6.92 2.12 231.19 —
Total liabilities
43.53 41.15 39.26 42.18 36.42 23.29 234.87 2.52
Additional Paid In Capital
723.51 720.49 705.79 694.73 675.35 475.62 2.41 —
Common Stock (Net)
— 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Retained Earnings
(704.76) (659.23) (594.47) (492.41) (356.28) (170.89) (58.66) (13.03)
Common Equity (Total)
18.76 61.26 111.28 201.37 318.66 304.71 (56.25) (12.17)
Shareholders Equity (Total)
18.76 61.26 111.28 201.37 318.66 304.71 (56.25) (12.17)
Shareholders Equity and Liabilities (Total)
62.28 102.41 150.55 243.55 355.08 328.01 178.61 —
Shares (Common)
3.18 3.16 2.75 2.73 2.71 2.28 0.21 —
Shareholders Equity (Tangible)
18.76 61.26 111.28 201.37 318.66 304.71 (56.25) —
Net Debt
(46.30) (76.76) (114.29) (189.61) (315.77) (304.82) (158.87) (24.86)
Total Debt
— — — 27.11 — — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates